• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺癌131I治疗后评估患者体内负荷方法的比较。

A comparison of methods for assessing patient body burden following 131I therapy for thyroid cancer.

作者信息

Thomas S R, Maxon H R, Fritz K M, Kereiakes J G, Connell W D

出版信息

Radiology. 1980 Dec;137(3):839-42. doi: 10.1148/radiology.137.3.7444070.

DOI:10.1148/radiology.137.3.7444070
PMID:7444070
Abstract

The effectiveness of three methods of assessing the patient body burden following 131I therapy was compared: (a) urine assay, (b) external exposure rate measurements, and (c) predictions based on a pretherapy diagnostic work-up. The urine assay method exhibited the greatest potential for error and personnel risk. The diagnostic work-up provided predictions of the body burden as a function of time, which may be applied to estimate the expected hospital stay. The direct external exposure rate survey showed the potential for being an accurate, reliable, and relatively safe method of monitoring the patient body burden.

摘要

比较了三种评估¹³¹I治疗后患者体内负荷的方法的有效性:(a)尿液分析,(b)外部暴露率测量,以及(c)基于治疗前诊断检查的预测。尿液分析方法显示出最大的误差可能性和人员风险。诊断检查提供了作为时间函数的体内负荷预测,可用于估计预期住院时间。直接外部暴露率调查显示出作为监测患者体内负荷的准确、可靠且相对安全的方法的潜力。

相似文献

1
A comparison of methods for assessing patient body burden following 131I therapy for thyroid cancer.甲状腺癌131I治疗后评估患者体内负荷方法的比较。
Radiology. 1980 Dec;137(3):839-42. doi: 10.1148/radiology.137.3.7444070.
2
Correlation between external exposure and activity in patients undergoing 131I thyroid cancer therapy.131I 甲状腺癌治疗患者的外部暴露与活动之间的相关性
Health Phys. 2008 Aug;95(2):227-33. doi: 10.1097/01.HP.0000310966.72052.70.
3
[Environmental radiation exposure of a thyroid cancer patient resulting from adjuvant iodine radiotherapy].[一名甲状腺癌患者因辅助碘放疗导致的环境辐射暴露]
Wiad Lek. 2001;54 Suppl 1:312-20.
4
Usefulness of 124I PET/CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I.124I PET/CT成像在预测转移性甲状腺癌患者接受131I治疗时的吸收剂量方面的效用。
Q J Nucl Med Mol Imaging. 2012 Dec;56(6):509-14.
5
131I effective half-life (Teff) for patients with thyroid cancer.甲状腺癌患者的131I有效半衰期(Teff)。
Health Phys. 2006 Aug;91(2):119-22. doi: 10.1097/01.HP.0000202232.98823.87.
6
Outpatient therapeutic 131I for thyroid cancer.甲状腺癌的门诊治疗性131I
J Nucl Med Technol. 2005 Mar;33(1):28-30.
7
NRC absorbed dose reconstruction for family member of 131I therapy patient: case study and commentary.131I治疗患者家庭成员的NRC吸收剂量重建:案例研究与评论
J Nucl Med. 2004 Apr;45(4):13N-6N, 37N.
8
Dosimetry in the therapy of metastatic differentiated thyroid cancer administering high 131I activity: the experience of Busto Arsizio Hospital (Italy).高活度¹³¹I治疗转移性分化型甲状腺癌的剂量学:布斯托·阿西齐奥医院(意大利)的经验
Q J Nucl Med Mol Imaging. 2012 Dec;56(6):515-21.
9
Radiation safety considerations for post-iodine-131 thyroid cancer therapy.
J Nucl Med. 1992 Jul;33(7):1402-5.
10
Reflections on cancer treatment and the federal agency regulations.
Radiology. 1980 Dec;137(3):865-6. doi: 10.1148/radiology.137.3.7444073.

引用本文的文献

1
The study of external dose rate and retained body activity of patients receiving 131I therapy for differentiated thyroid carcinoma.分化型甲状腺癌患者接受¹³¹I治疗时的外照射剂量率及体内滞留活度研究。
Int J Environ Res Public Health. 2014 Oct 21;11(10):10991-1003. doi: 10.3390/ijerph111010991.
2
Estimation of effective half life of clearance of radioactive Iodine (I) in patients treated for hyperthyroidism and carcinoma thyroid.对接受甲状腺功能亢进症和甲状腺癌治疗的患者体内放射性碘(I)清除有效半衰期的估计。
Indian J Nucl Med. 2010 Apr;25(2):49-52. doi: 10.4103/0972-3919.72686.
3
Measurement of the radioactive body burden in patients receiving iodine-131 treatment for carcinoma of the thyroid.
接受碘-131治疗甲状腺癌患者放射性体内负荷的测量。
Eur J Nucl Med. 1997 Apr;24(4):464. doi: 10.1007/BF00881823.
4
Toxicity from treatment of neuroblastoma with 131I-meta-iodobenzylguanidine.
Eur J Nucl Med. 1988;14(7-8):337-40. doi: 10.1007/BF00254379.